An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease.
Authors
Felce, Suet Ling
Dong, Danning
Yao, Xuan
Liu, Guihai
Chen, Ji-Li
Wellington, Dannielle
Dominey-Foy, Delaney CC
Jin, Chen
Wang, Wenbo
Hamid, Megat Abd
Fernandes, Ricardo A
Wang, Beibei
Ashley, Neil
Rostron, Timothy
Waugh, Craig
Sopp, Paul
Beveridge, Ryan
Dold, Christina
Dejnirattisa, Wanwisa
Liu, Chang
Kurupati, Prathiba
Nassiri, Isar
Watson, Robert A
Taylor, Chelsea A
Curion, Fabiola
Revale, Santiago
Ferreira, Ricardo C
COMBAT Consortium
Townsend, Alain
Ho, Ling-Pei
Dendrou, Calliope
McKeating, Jane A
Fairfax, Benjamin P
McMichael, Andrew J
Ogg, Graham
Knight, Julian C
Publication Date
2022-01Journal Title
Nat Immunol
ISSN
1529-2908
Publisher
Springer Science and Business Media LLC
Volume
23
Issue
1
Pages
50-61
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Peng, Y., Felce, S. L., Dong, D., Penkava, F., Mentzer, A. J., Yao, X., Liu, G., et al. (2022). An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease.. Nat Immunol, 23 (1), 50-61. https://doi.org/10.1038/s41590-021-01084-z
Description
Funder: RCUK | Medical Research Council (MRC); doi: https://doi.org/10.13039/501100000265
Funder: Chinese Academy of Medical Sciences (CAMS); doi: https://doi.org/10.13039/501100005150
Funder: Wellcome Trust (Wellcome); doi: https://doi.org/10.13039/100004440
Abstract
NP105-113-B*07:02-specific CD8+ T cell responses are considered among the most dominant in SARS-CoV-2-infected individuals. We found strong association of this response with mild disease. Analysis of NP105-113-B*07:02-specific T cell clones and single-cell sequencing were performed concurrently, with functional avidity and antiviral efficacy assessed using an in vitro SARS-CoV-2 infection system, and were correlated with T cell receptor usage, transcriptome signature and disease severity (acute n = 77, convalescent n = 52). We demonstrated a beneficial association of NP105-113-B*07:02-specific T cells in COVID-19 disease progression, linked with expansion of T cell precursors, high functional avidity and antiviral effector function. Broad immune memory pools were narrowed postinfection but NP105-113-B*07:02-specific T cells were maintained 6 months after infection with preserved antiviral efficacy to the SARS-CoV-2 Victoria strain, as well as Alpha, Beta, Gamma and Delta variants. Our data show that NP105-113-B*07:02-specific T cell responses associate with mild disease and high antiviral efficacy, pointing to inclusion for future vaccine design.
Keywords
Article, /631/250/2152/1566/1571, /692/699/255/2514, article
Identifiers
s41590-021-01084-z, 1084
External DOI: https://doi.org/10.1038/s41590-021-01084-z
This record's URL: https://www.repository.cam.ac.uk/handle/1810/332148
Rights
Licence:
http://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.